8th and final DSMB due anytime, though I wouldn't be surprised if the last DSMB report came out along with the announcement of hitting 250 events/end of dosing. Average time in between DSMBs is 123 days. Gap between 6th (2/26/28) and 7th (8/7/18) was 162 days.

Longest patient (assuming still in trial) now dosing for 37 months (first patient dosing 11/11/2015). Mean dosing (per AHA poster) estimated to be 26 months (at least 6 months, range 6 to 38 months).

Reported MACE events at ~200 at AGM 9/12/18 with events occurring at 10-15 per month. Fast forward three months to today and that puts BETonMACE in the projected range of 230-245.

250 MACE events and end of dosing by end of year? That still seems viable. But if no update by year end, the Resverlogix presentation at Biotech Showcase Jan 7-9, 2019 could be a ripe time for this announcement. 

Once 250 events/end of dosing is announced, guidance from company is that adjudication of all events will take ~2 months and top-line data will be announced immediately after adjudication completion.

An update to the outdated BETonMACE listings for ClinicalTrials.gov and/or clinicaltrialsregister.eu may occur soon (IR indicated to me early 2019) that reveal changes to trial protocol and trial status.

Publication of BETonMACE trial design, rationale and baseline data in major journal could also come at anytime.

We'll know if Resverlogix is presenting BETonMACE data in the mid-March ACC 2019 late breaking clinical trial session by the end of January.

Tick tock.

BDAZ